SCHEMBL495444

SCHEMBL495444

CCC(CCCCCCCCCCCCCCCC(=O)OC)C(=O)OC

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.50
TSHR P16473 4/20 0.48
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
ZDHHC7 Q9NXF8 1/20 0.43
CYP3A4 P08684 1/20 0.41
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PPARG P37231 2/20 0.41
PABPC1 P11940 1/20 0.40
APOBEC3A P31941 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
DGKA P23743 1/20 0.40
USP2 O75604 1/20 0.40
EPHX2 P34913 1/20 0.39
PPARA Q07869 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL579546 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL494780 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL494876 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL495153 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL493825 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL20511325 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL493914 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL495124 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL494673 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA
SCHEMBL495629 1.00 CA1 (0.65) CA1CA2L3MBTL1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340485-B2 Process for preparing esters from formates and olefinically unsaturated compounds EVONIK INDUSTRIES AG (DE) 2016-05-17 US disclosed
US-20140309435-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS EVONIK INDUSTRIES AG (DE) 2014-10-16 US disclosed
WO-2013042797-A1 PROCESS FOR PRODUCING SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-03-28 WO disclosed
US-20130072648-A1 SOLID CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR PRODUCING OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-03-21 US disclosed
US-8105970-B2 Olefin polymerization catalyst component and production process thereof, and production proces of olefin polymerization catalyst and olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-31 US disclosed
US-20110245439-A1 OLEFIN POLYMERIZATION CATALYST COMPONENT AND PRODUCTION PROCESS THEREOF, AND PRODUCTION PROCES OF OLEFIN POLYMERIZATION CATALYST AND OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140309435-A1 PROCESS FOR PREPARING ESTERS FROM FORMATES AND OLEFINICALLY UNSATURATED COMPOUNDS FDPS, ELOVL6, ELOVL3 CA1 3163/4885CA2 3961/4885L3MBTL1 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.